A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition:   Mantle Cell Lymphoma (MCL) Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Rituximab Sponsor:   AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials